Maintenance phase is the period after active loading where the goal is stable benefit with lower side-effect risk.
Why it matters
Stable performance over time usually comes from consistent timing and dose, not constant escalation.
Stabilization goals and plateaus
Use a maintenance window to identify when effects have plateaued:
- early signal: first week of smoother adherence and reduced symptom spikes
- middle stabilization: similar response across repeated cycles
- plateau: no meaningful improvement for 10–14 days with reliable logging
Metrics to monitor
- adherence consistency
- sleep or focus trend consistency
- adverse-effect frequency
- dose tolerance drift
Dose-reduction and reevaluation rules
- reduce dose by one step (or one split) before adding new compounds
- keep the reduced dose for at least one full cycle before another change
- reassess every 14–30 days or sooner if adverse effects increase
Cycling back into loading
Return to a loading approach only when:
- clear effect fade occurs after 2–3 consistent maintenance cycles
- no safety alerts or overlapping adverse patterns are active
- clinician or clinician-guided review supports a temporary re-acceleration
If effects fade with new medical symptoms, revert to evaluation mode and pause progression.
Practical action step
Capture a weekly baseline metric set and decide each week whether you are in plateau, stable, or decline state before any protocol change.
Uncertainty and limits
- Evidence is limited on ideal maintenance duration by compound class outside clinical trial contexts.
- Evidence is limited on whether all benefits persist equally across different lifestyle disruptions.
Cross-site references
How this appears in Unfair
Unfair uses maintenance logic to lower volatile recommendations, favoring lower-change plans unless objective outcomes decline.
Clinical safety note
If adverse events increase after increasing complexity, immediately revert to simpler dosing and seek clinician input before attempting re-escalation.